Caribou Biosciences (CRBU) Shares Outstanding (Weighted Average) (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Shares Outstanding (Weighted Average) data on file, last reported at $95.9 million in Q1 2026.

• Quarterly Shares Outstanding (Weighted Average) rose 3.43% year-over-year to $95.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95.9 million (up 3.43% YoY) and the FY2025 annual result came in at $93.4 million, up 3.4% from the prior year.
• Shares Outstanding (Weighted Average) improved to $95.9 million in Q1 2026 per CRBU's latest filing, from $93.4 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $95.9 million in Q1 2026 and bottomed at $60.5 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $89.3 million (2024), against an average of $79.5 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) jumped 537.37%; it then advanced 1.06% in 2023.
• Tracing CRBU's Shares Outstanding (Weighted Average) over 5 years: stood at $60.8 million in 2022, then advanced by 21.39% to $73.8 million in 2023, then advanced by 22.37% to $90.3 million in 2024, then increased by 3.4% to $93.4 million in 2025, then increased by 2.65% to $95.9 million in 2026.
• Per Business Quant, the three latest CRBU Shares Outstanding (Weighted Average) figures stand at $95.9 million (Q1 2026), $93.4 million (Q4 2025), and $93.0 million (Q3 2025).

Peer Comparison